6 recruiting, 4 completed, 3 active not recruiting, 3 terminated. 13 Phase 2, 7 Phase 1, 2 Phase 3, 1 Not applicable.
Follow Dedifferentiated Liposarcoma: new trials by email Literature Review of Dedifferentiated Liposarcoma trials Research Report on Dedifferentiated Liposarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers and as Monotherapy in Participants With Selected Sarcomas STC-15 in combination with toripalimab, STC-15 monotherapy - Solid Tumor, Sarcoma | Phase 1 / Phase 2 | Recruiting | STORM Therapeutics LTD | 107 | 2025-05-05 | 2026-10-22 |
| A Phase 1 Study of Neoadjuvant Abemaciclib in Combination With Radiation Therapy for Liposarcomas Abemaciclib, Computed Tomography, Magnetic Resonance Imaging - Retroperitoneal Sarcoma, Liposarcoma | Phase 1 | Recruiting | University of Washington | 18 | 2025-03-19 | 2026-09-17 |
| A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma Mirdametinib, Palbociclib - Well Differentiated Liposarcoma, Dedifferentiated Liposarcoma | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 54 | 2025-02-19 | 2026-09-16 |
| Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma Biopsy, Chest Computed Tomography, Chest Radiography - Adult Pleomorphic Rhabdomyosarcoma, AJCC Grade 2 Sarcoma | Not applicable | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 1582 | 2025-01-28 | 2024-07-30 |
| A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors OKN4395, Pembrolizumab, Fasting - Solid Tumours, Sarcoma | Phase 1 | Recruiting | Epkin | 146 | 2025-01-23 | 2026-06-11 |
| First-line Treatment of Advanced/unresectable DDLPS Liposomal Doxorubicin (Doxil), Apatinib, Camrelizumab - Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS) | Phase 2 | Not yet recruiting | Fudan University | 49 | 2024-12-01 | 2024-11-19 |
| A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI) Pemigatinib, Retifanlimab - Dedifferentiated Liposarcoma | Phase 2 | Recruiting | Lund University Hospital | 33 | 2024-06-20 | 2026-08-27 |
| NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) Surgical resection, Proton beam radiation therapy, Pazopanib - Adipocytic Neoplasm, Liposarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 139 | 2024-03-27 | 2026-08-03 |
| Real-world Study of Dedifferentiated Liposarcoma Patients in China Dedifferentiated Liposarcoma | Completed | Boehringer Ingelheim | 1390 | 2024-03-13 | 2025-07-10 | |
| A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma Etrumadenant, Zimberelimab - Dedifferentiated Liposarcoma, Soft Tissue Sarcoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2023-05-23 | 2026-10-22 |
| TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma TQB3616 capsule, TQB3616 placebo - Dedifferentiated Liposarcoma | Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 26 | 2022-08-08 | 2025-11-21 |
| Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma RAIN-32, Trabectedin - Dedifferentiated Liposarcoma | Phase 3 | Terminated | Rain Oncology Inc | 175 | 2021-07-14 | 2025-01-14 |
| Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas DCC-3014, Avelumab - Sarcoma, Advanced Sarcoma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 32 | 2020-01-22 | 2025-08-28 |
| Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors TP-1287 - Advanced Solid Tumors, Sarcoma | Phase 1 | Terminated | Sumitomo Pharma America, Inc. | 74 | 2018-12-26 | 2024-09-19 |
| Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery Ipilimumab, Nivolumab, Radiation Therapy - Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 32 | 2017-10-04 | 2026-09-14 |
| Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy - Sarcoma, Fibrosarcoma | Phase 2 | Unknown | Maria Sklodowska-Curie National Research Institute of Oncology | 46 | 2017-02-11 | 2021-01-22 |
| Study of Abemaciclib in Dedifferentiated Liposarcoma Abemaciclib - Sarcoma, Dedifferentiated Liposarcoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 33 | 2016-07-01 | 2026-06-08 |
| Selinexor in Advanced Liposarcoma Selinexor, Placebo - Dedifferentiated Liposarcoma | Phase 2 / Phase 3 | Completed | Karyopharm Therapeutics Inc | 342 | 2016-01-04 | 2023-01-23 |
| Ph II Cabazitaxel DD Liposarcoma Cabazitaxel - Dedifferentiated Liposarcoma | Phase 2 | Completed | European Organisation for Research and Treatment of Cancer - EORTC | 42 | 2014-10-01 | 2021-09-14 |
| Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma IPI-504 - Dedifferentiated Liposarcoma | Phase 2 | Withdrawn | Infinity Pharmaceuticals, Inc. | 2010-01-01 | 2015-04-14 |
Liposarcoma (20) · Sarcoma (11) · Leiomyosarcoma (6) · Dermatofibrosarcoma (5) · Histiocytoma, Malignant Fibrous (5) · Sarcoma, Synovial (4) · Fibrosarcoma (3) · Liposarcoma, Myxoid (3) · Neurofibrosarcoma (3) · Chondrosarcoma, Extraskeletal Myxoid (2) · Hemangiosarcoma (2) · Sarcoma, Clear Cell (2) · Carcinoma, Non-Small-Cell Lung (1) · Colorectal Neoplasms (1) · Disorders of Sex Development (1)
Neoplasms by Histologic Type (20) · Neoplasms, Connective and Soft Tissue (20) · Neoplasms (19) · Neoplasms, Adipose Tissue (19) · Sarcoma (9) · Neoplasms, Connective Tissue (7) · Neoplasms, Fibrous Tissue (6) · Neoplasms, Muscle Tissue (6) · Histiocytoma (5) · Neoplasms, Nerve Tissue (3) · Nervous System Diseases (3) · Nervous System Neoplasms (3) · Neurofibroma (3) · Neuromuscular Diseases (3) · Peripheral Nervous System Diseases (3)
Radiation (2) · Radiotherapy (2) · abemaciclib (2) · selinexor (2) · Angptl4 protein, mouse (1) · Biopsy (1) · CTLA-4 Antigen (1) · Doxorubicin (1) · Famotidine (1) · Histamine H2 Antagonists (1) · Ifosfamide (1) · Ipilimumab (1) · Magnetic Resonance Spectroscopy (1) · Nivolumab (1) · Proton Therapy (1)
Memorial Sloan Kettering Cancer Center (4) · Boehringer Ingelheim (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · ECOG-ACRIN Cancer Research Group (1) · Epkin (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fudan University (1) · Infinity Pharmaceuticals, Inc. (1) · Karyopharm Therapeutics Inc (1) · Lund University Hospital (1) · M.D. Anderson Cancer Center (1) · Maria Sklodowska-Curie National Research Institute of Oncology (1) · Rain Oncology Inc (1) · STORM Therapeutics LTD (1) · St. Jude Children's Research Hospital (1)
United States (13) · United Kingdom (4) · Belgium (3) · China (3) · France (3) · Italy (3) · Canada (2) · Germany (2) · Poland (2) · Spain (2) · Sweden (2) · Australia (1) · Austria (1) · Georgia (1) · Hong Kong (1)
Sandra D'Angelo, MD (2) · Christina L Roland (1) · Jeremy Sharib, MD (1) · Jessica Gartrell, MD (1) · Kenneth Cardona (1) · Larry Hayward, MD (1) · Mark Dickson, MD (1) · Olayode Babatunde, MD (1) · Sandra Tong, MD (1) · Zhiguo Luo, MD, PhD (1)
PMID 30249211, PMID 35394800, PMID 42194972
2015 (1), UG1CA189828 (1)